Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3′-diindolylmethane (Ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells

Prostate

Volumn 71, Issue 13, 2011, Pages 1401-1412

  Abdelbaqi, Khalil ^a   Lack, Nathan ^b   Guns, Emma Tomlinson ^b   Kotha, Leela ^c,d   Safe, Stephen ^c,d   Sanderson, J Thomas ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c TEXAS A AND M UNIVERSITY   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

androgen receptor; dihydrotestosterone; immunofluorescence; LNCaP cells; prostate specific antigen; ring DIMs

Indexed keywords

3,3' DIINDOLYLMETHANE; 4,4' DIBROMO 4,4' DICHLORO 7,7' DIBROMO 3,3' DIINDOLYLMETHANE; 7,7' DICHLORO 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYTOPLASM PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; PROBASIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LEVEL; CELL NUCLEUS; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; SUBSTITUTION REACTION; WILD TYPE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INDOLES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 80051663254     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21356     Document Type: Article

References (59)

1. Tang DG, Porter AT,. Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 1997; 32 (4): 284-293. (Pubitemid 27374201)
2. Nupponen N, Visakorpi T,. Molecular biology of progression of prostate cancer. Eur Urol 1999; 35 (5-6): 351-354. (Pubitemid 29229532)
3. Landis SH, Murray T, Bolden S, Wingo PA,. Cancer statistics, 1999. CA Cancer J Clin 1999; 49 (1): 8-31. (Pubitemid 29094959)
4. Kristal AR, Lampe JW,. Brassica vegetables and prostate cancer risk: A review of the epidemiological evidence. Nutr Cancer 2002; 42 (1): 1-9. (Pubitemid 35007000)
5. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP,. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 1994; 86 (2): 126-131.
6. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, Xu P, Spencer D,. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007; 28 (3): 572-583. (Pubitemid 46523353)
7. Nachshon-Kedmi M, Yannai S, Haj A, Fares FA,. Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 2003; 41 (6): 745-752. (Pubitemid 36555879)
8. Bradlow HL, Michnovicz J, Telang NT, Osborne MP,. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991; 12 (9): 1571-1574.
9. Nachshon-Kedmi M, Yannai S, Fares FA,. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. Br J Cancer 2004; 91 (7): 1358-1363. (Pubitemid 39424798)
10. Li Y, Li X, Sarkar FH,. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 2003; 133 (4): 1011-1019. (Pubitemid 36407118)
11. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH,. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20 (23): 2927-2936. (Pubitemid 33027760)
12. Wattenberg LW, Loub WD,. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 1978; 38 (5): 1410-1413. (Pubitemid 8323347)
13. Nachshon-Kedmi M, Fares FA, Yannai S,. Therapeutic activity of 3,3'-diindolylmethane on prostate cancer in an in vivo model. Prostate 2004; 61 (2): 153-160. (Pubitemid 39244702)
14. Chang X, Tou JC, Hong C, Kim HA, Riby JE, Firestone GL, Bjeldanes LF,. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005; 26 (4): 771-778. (Pubitemid 41214339)
15. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE,. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 2004; 32 (6): 632-638. (Pubitemid 38668156)
16. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH,. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006; 66 (20): 10064-10072. (Pubitemid 44672060)
17. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH,. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67 (7): 3310-3319. (Pubitemid 46724870)
18. Kannagi R, Yin J, Miyazaki K, Izawa M,. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim Biophys Acta 2008; 1780 (3): 525-531. (Pubitemid 351381253)
19. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP,. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58 (15): 3344-3352. (Pubitemid 28371075)
20. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW,. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97 (20): 10990-10995.
21. Moretti RM, Montagnani Marelli M, Motta M, Limonta P,. Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. Int J Cancer 2001; 92 (5): 733-737. (Pubitemid 32385718)
22. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, Kishimoto T, Sano H,. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002; 51 (2): 108-116.
23. Jiang M, Shappell SB, Hayward SW,. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. J Cell Biochem 2004; 91 (3): 513-527.
24. Jarvis MC, Gray TJ, Palmer CN,. Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line. Oncogene 2005; 24 (55): 8211-8215. (Pubitemid 41759820)
25. Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, Ringel MD,. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 2006; 69 (5): 1564-1570.
26. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF,. Plant-derived 3,3'-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003; 278 (23): 21136-21145. (Pubitemid 36806427)
27. Chen CD, Sawyers CL,. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002; 22 (8): 2862-2870. (Pubitemid 34263006)
28. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308. (Pubitemid 38501396)
29. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC,. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005; 64 (2): 160-167. (Pubitemid 40791765)
30. Zhang L, Charron M, Wright WW, Chatterjee B, Song CS, Roy AK, Brown TR,. Nuclear factor-kappaB activates transcription of the androgen receptor gene in Sertoli cells isolated from testes of adult rats. Endocrinology 2004; 145 (2): 781-789. (Pubitemid 38183821)
31. Denmeade SR, Isaacs JT,. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2 (5): 389-396. (Pubitemid 37328952)
32. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G,. Cancer of the prostate. Crit Rev Oncol Hematol 2005; 56 (3): 379-396. (Pubitemid 41677619)
33. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61 (4): 332-353. (Pubitemid 39571710)
34. Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL,. Prostate cancer: A clinical and basic science review. J Androl 1997; 18 (1): 15-20. (Pubitemid 27114458)
35. McDougal A, Sethi Gupta M, Ramamoorthy K, Sun G, Safe SH,. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 2000; 151 (2): 169-179. (Pubitemid 30156791)
36. McDougal A, Gupta MS, Morrow D, Ramamoorthy K, Lee JE, Safe SH,. Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. Breast Cancer Res Treat 2001; 66 (2): 147-157. (Pubitemid 32521421)
37. Tavassoli P, Snoek R, Ray M, Rao LG, Rennie PS,. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells. Prostate 2007; 67 (4): 416-426. (Pubitemid 46341083)
38. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD,. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11 (3): 459-476. (Pubitemid 39331277)
39. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP,. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154 (2 Pt 1): 448-453.
40. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L,. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2001; 19 (1): 62-71. (Pubitemid 32063480)
41. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ,. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 1998; 159 (1): 149-153. (Pubitemid 27525592)
42. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M,. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 1997; 15 (8): 2928-2938. (Pubitemid 27330021)
43. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM,. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000; 78 (2): 123-129. (Pubitemid 30650341)
44. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C,. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 1997; 129 (1): 17-26. (Pubitemid 27229213)
45. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP,. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277 (29): 26321-26326. (Pubitemid 34967123)
46. Chintharlapalli S, Papineni S, Safe S,. 1,1-Bis(3'-indolyl)-1-(p- substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways. Mol Pharmacol 2007; 71 (2): 558-569. (Pubitemid 46151072)
47. Blanchere M, Berthaut I, Portois MC, Mestayer C, Mowszowicz I,. Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J Steroid Biochem Mol Biol 1998; 66 (5-6): 319-326. (Pubitemid 28545126)
48. Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S, Shikama H,. Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun 2002; 294 (4): 779-784. (Pubitemid 34687184)
49. Vernon SE, Williams WD,. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol 1983; 130 (1): 95-98. (Pubitemid 13026591)
50. Duffy MJ,. PSA as a marker for prostate cancer: A critical review. Ann Clin Biochem 1996; 33 (Pt 6): 511-519. (Pubitemid 26397713)
51. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ,. Molecular mechanisms of androgen action. Vitam Horm 1994; 49: 383-432.
52. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J,. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271 (11): 6379-6388. (Pubitemid 26095448)
53. Webber MM, Waghray A, Bello D,. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1 (10): 1089-1094.
54. Cohen P, Peehl DM, Graves HC, Rosenfeld RG,. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142 (3): 407-415. (Pubitemid 24285445)
55. Pereira de Jesus-Tran K, Cote PL, Cantin L, Blanchet J, Labrie F, Breton R,. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006; 15 (5): 987-999.
56. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA,. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275 (34): 26164-26171.
57. Golas CL, Prokipcak RD, Okey AB, Manchester DK, Safe S, Fujita T,. Competitive binding of 7-substituted-2,3-dichlorodibenzo-p-dioxins with human placental ah receptor-A QSAR analysis. Biochem Pharmacol 1990; 40 (4): 737-741. (Pubitemid 20246578)
58. Romkes M, Piskorska-Pliszczynska J, Keys B, Safe S, Fujita T,. Quantitative structure-activity relationships: Analysis of interactions of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2-substituted analogues with rat, mouse, guinea pig, and hamster cytosolic receptor. Cancer Res 1987; 47 (19): 5108-5111. (Pubitemid 17146481)
59. Denomme MA, Homonoko K, Fujita T, Sawyer T, Safe S,. Effects of substituents on the cytosolic receptor-binding avidities and aryl hydrocarbon hydroxylase induction potencies of 7-substituted 2,3-dichlorodibenzo-p-dioxins. A quantitative structure-activity relationship analysis. Mol Pharmacol 1985; 27 (6): 656-661. (Pubitemid 15010698)